Use of Platelet-Rich Plasma in the Management of Alopecia Areata

In two phase 3 trials, this study found that oral baricitinib significantly improved hair regrowth compared to placebo in adults with severe alopecia areata after 36 weeks, though longer trials are needed to ascertain its long-term efficacy and safety.

This review discusses the potential use of platelet-rich plasma for treating alopecia areata but reports no new experimental findings, noting the need for standardized protocols and larger studies to evaluate its efficacy.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

This case study reports that combining platelet-rich plasma with intradermal triamcinolone acetonide improved hair regrowth and fiber diameter in one patient with alopecia areata compared to triamcinolone alone.

This case report describes a patient with corticosteroid-resistant ophiasis alopecia areata who experienced prompt hair regrowth after receiving platelet-rich plasma injections.

This study found that platelet-rich plasma may have a role in treating chronic alopecia areata, but more long-term follow-up studies are needed to confirm its effectiveness and success rate.

In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.